Brand Name
Rapiblyk
Generic Name
Landiolol
View Brand Information FDA approval date: April 29, 2025
Classification: beta-Adrenergic Blocker
Form: Injection
What is Rapiblyk (Landiolol)?
RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter. RAPIBLYK is a beta adrenergic blocker indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment
Brand Information
RAPIBLYK (landiolol)
1INDICATIONS AND USAGE
RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.
2DOSAGE FORMS AND STRENGTHS
For injection: White to almost white lyophilized powder in a single-dose vial containing 280 mg of landiolol (equivalent to 300 mg landiolol HCl).
3CONTRAINDICATIONS
RAPIBLYK is contraindicated in patients with:
- Severe sinus bradycardia, sick sinus syndrome, heart block greater than first degree
- Decompensated heart failure
- Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.
- Pulmonary hypertension: May precipitate cardiorespiratory decompensation.
- Hypersensitivity reactions, including anaphylaxis, to landiolol or any of the inactive ingredients
4DESCRIPTION
RAPIBLYK (landiolol) for injection is a beta-1 adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 4 minutes). Landiolol is:
- [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propionate and has the following structure:
- The active pharmaceutical ingredient is the hydrochloride salt of landiolol, which has the empirical formula C
- Landiolol HCl is a white crystalline powder. It is a relatively hydrophilic compound, which is very soluble in water.
RAPIBLYK is supplied as a single presentation of 280 mg landiolol (equivalent to 300 mg landiolol HCl) as a white to almost white sterile lyophilized powder for intravenous injection in a 50 mL vial. Inactive ingredients include 300 mg of mannitol and sodium hydroxide as needed to adjust pH.
5CLINICAL STUDIES
In 5 randomized, double-blind, placebo-controlled studies, treatment of 317 adults with supraventricular tachycardia with landiolol decreased heart rate in 40-90% of treated patients within about 10 minutes, compared to 0-11% of patients who received placebo; heart rate decrease was defined as a >20% decrease in heart rate or a heart rate <100 bpm or at least intermittent cessation of the arrhythmia. The infused dose of landiolol in these studies ranged from 9.3 to 74.6 mcg/kg/min (equivalent to 10 to 80 mcg/kg/min landiolol hydrochloride).